MXPA06013133A - Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. - Google Patents
Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.Info
- Publication number
- MXPA06013133A MXPA06013133A MXPA06013133A MXPA06013133A MXPA06013133A MX PA06013133 A MXPA06013133 A MX PA06013133A MX PA06013133 A MXPA06013133 A MX PA06013133A MX PA06013133 A MXPA06013133 A MX PA06013133A MX PA06013133 A MXPA06013133 A MX PA06013133A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- sexual dysfunction
- female sexual
- pharmaceutical formulations
- female
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Abstract
La presente invencion se relaciona con el uso de una combinacion de un inhibidor de PDE5 y testosterona para la preparacion de un medicamento para el tratamiento de la Disfuncion Sexual Femenina.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04076402 | 2004-05-11 | ||
EP04078033 | 2004-11-04 | ||
EP04078381 | 2004-12-13 | ||
EP04078380 | 2004-12-13 | ||
EP04078455 | 2004-12-21 | ||
PCT/NL2005/000355 WO2005107810A2 (en) | 2004-05-11 | 2005-05-11 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06013133A true MXPA06013133A (es) | 2007-05-23 |
Family
ID=35094148
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06013133A MXPA06013133A (es) | 2004-05-11 | 2005-05-11 | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. |
MX2013000851A MX347237B (es) | 2004-05-11 | 2005-05-11 | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013000851A MX347237B (es) | 2004-05-11 | 2005-05-11 | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. |
Country Status (22)
Country | Link |
---|---|
US (5) | US8227453B2 (es) |
EP (1) | EP1750766B1 (es) |
JP (3) | JP2007537247A (es) |
KR (1) | KR101292492B1 (es) |
CN (2) | CN102512681A (es) |
AU (1) | AU2005239962B2 (es) |
BR (1) | BRPI0511079A (es) |
CA (1) | CA2566699C (es) |
CY (1) | CY1114448T1 (es) |
DK (1) | DK1750766T3 (es) |
ES (1) | ES2429444T3 (es) |
HK (1) | HK1108128A1 (es) |
HR (1) | HRP20130892T1 (es) |
MX (2) | MXPA06013133A (es) |
NZ (1) | NZ551356A (es) |
PL (1) | PL1750766T3 (es) |
PT (1) | PT1750766E (es) |
RS (1) | RS52945B (es) |
RU (2) | RU2436579C2 (es) |
SI (1) | SI1750766T1 (es) |
WO (1) | WO2005107810A2 (es) |
ZA (1) | ZA200609974B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2436579C2 (ru) | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2012107090A1 (en) * | 2011-02-10 | 2012-08-16 | Synthon Bv | Granulated composition comprising tadalafil and a disintegrant |
WO2012107092A1 (en) * | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
WO2012107541A1 (en) * | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
KR102158948B1 (ko) | 2011-05-13 | 2020-09-24 | 이비 아이피 하이브리탭스 비.브이. | 약물 전달 시스템 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
WO2013122470A1 (en) * | 2012-02-17 | 2013-08-22 | Emotional Brain B.V. | Methods of differentiating hypoactive sexual desire disorder and/or female sexual arousal disorder |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
KR101484481B1 (ko) * | 2014-08-07 | 2015-01-20 | 주식회사 다림바이오텍 | Pde-5 저해제를 포함하는 설하분무제의 제조방법 및 이에 의하여 제조된 설하분무용 조성물 |
EP3248592A1 (en) * | 2016-05-25 | 2017-11-29 | EB IP Hybritabs B.V. | Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
US4521421A (en) | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
DK169601B1 (da) | 1983-10-17 | 1994-12-19 | Duphar Int Res | Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
US5015646A (en) | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
CA1335106C (en) | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
US6174890B1 (en) | 1994-06-02 | 2001-01-16 | Dan Riga | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
CZ278497A3 (cs) | 1995-03-14 | 1998-04-15 | Vivus, Incorporated | Způsob a sestava zařízení k prevenci impotence |
US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
CA2219082A1 (en) | 1995-05-15 | 1996-11-21 | Beth Israel Deaconess Medical Center, Inc. | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
AU756136B2 (en) | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
JP2001520999A (ja) | 1997-10-28 | 2001-11-06 | アシビ, エルエルシー | 女性の性的機能不全の処置 |
US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US6246436B1 (en) | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
TW542719B (en) | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
EP1173167A4 (en) | 1999-04-30 | 2004-07-14 | Lilly Icos Llc | TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS |
US6428769B1 (en) * | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
US7258850B2 (en) | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
US6632419B2 (en) | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
CA2377339A1 (en) * | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | Administration of growth hormone (hgh) for the therapy of sexual functional disorders |
RU2180591C2 (ru) | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
DE10016548A1 (de) | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6242436B1 (en) | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
CN1473047A (zh) | 2000-08-30 | 2004-02-04 | ������ҩ������˾ | 治疗男性勃起功能障碍和增强性冲动的方法 |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
SK287066B6 (sk) | 2000-09-29 | 2009-11-05 | Solvay Pharmaceuticals B. V. | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy |
US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
EP1383502A4 (en) | 2001-03-06 | 2007-07-25 | Strakan Int Ltd | COMPOUNDS AND METHOD FOR TREATING UROGENITAL DISORDER |
EA006154B1 (ru) | 2001-03-28 | 2005-10-27 | Пфайзер Инк. | N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
US20030022875A1 (en) | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
JP2007516949A (ja) | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
WO2005094827A1 (en) | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
RU2445095C2 (ru) | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
RU2436579C2 (ru) | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
KR20080016552A (ko) | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
WO2006127057A1 (en) | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
WO2007054791A2 (en) | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
KR101694551B1 (ko) | 2007-11-28 | 2017-01-09 | 유씨비 파마 게엠베하 | 로티고틴의 다형 형태 |
-
2005
- 2005-05-11 RU RU2006143652/15A patent/RU2436579C2/ru active
- 2005-05-11 PL PL05745467T patent/PL1750766T3/pl unknown
- 2005-05-11 MX MXPA06013133A patent/MXPA06013133A/es active IP Right Grant
- 2005-05-11 CN CN2012100087326A patent/CN102512681A/zh active Pending
- 2005-05-11 SI SI200531779T patent/SI1750766T1/sl unknown
- 2005-05-11 PT PT57454670T patent/PT1750766E/pt unknown
- 2005-05-11 CA CA2566699A patent/CA2566699C/en active Active
- 2005-05-11 NZ NZ551356A patent/NZ551356A/en not_active IP Right Cessation
- 2005-05-11 EP EP05745467.0A patent/EP1750766B1/en active Active
- 2005-05-11 MX MX2013000851A patent/MX347237B/es unknown
- 2005-05-11 JP JP2007513085A patent/JP2007537247A/ja not_active Withdrawn
- 2005-05-11 WO PCT/NL2005/000355 patent/WO2005107810A2/en active Application Filing
- 2005-05-11 KR KR1020067025958A patent/KR101292492B1/ko active IP Right Grant
- 2005-05-11 BR BRPI0511079-3A patent/BRPI0511079A/pt not_active Application Discontinuation
- 2005-05-11 DK DK05745467.0T patent/DK1750766T3/da active
- 2005-05-11 ES ES05745467T patent/ES2429444T3/es active Active
- 2005-05-11 RS RS20130420A patent/RS52945B/en unknown
- 2005-05-11 CN CN200580018927.7A patent/CN101027061B/zh active Active
- 2005-05-11 AU AU2005239962A patent/AU2005239962B2/en active Active
-
2006
- 2006-11-10 US US11/595,778 patent/US8227453B2/en active Active
- 2006-11-29 ZA ZA200609972A patent/ZA200609974B/xx unknown
-
2008
- 2008-02-27 HK HK08102164.8A patent/HK1108128A1/xx not_active IP Right Cessation
-
2011
- 2011-08-08 RU RU2011133242A patent/RU2636501C2/ru active
-
2012
- 2012-06-21 US US13/529,813 patent/US9192669B2/en active Active
-
2013
- 2013-05-23 JP JP2013108887A patent/JP5923459B2/ja active Active
- 2013-09-20 HR HRP20130892TT patent/HRP20130892T1/hr unknown
- 2013-10-02 CY CY20131100849T patent/CY1114448T1/el unknown
-
2015
- 2015-01-20 JP JP2015008375A patent/JP6166739B2/ja active Active
- 2015-09-25 US US14/866,547 patent/US9700566B2/en active Active
-
2017
- 2017-06-12 US US15/620,576 patent/US10441592B2/en active Active
-
2019
- 2019-09-06 US US16/563,638 patent/US20190388435A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06013133A (es) | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. | |
YU30004A (sh) | Upotreba flibanserina u lečenju seksualnih poremećaja | |
TW200603807A (en) | Method for the treatment of premenstrual and other female sexual disorders | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
MY145439A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
GB2431346B (en) | A combination composition comprising paracetamol and ibuprofen | |
MY151048A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
IL191280A0 (en) | Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction | |
WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
ZA201000581B (en) | 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof | |
TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
TW200716082A (en) | Combination and use of drugs | |
PL1781292T3 (pl) | Formulacja o przedłużonym uwalnianiu 3-amino-8-(1-piperazynylo)-2H-1-benzopiran-2-onu | |
HK1073109A1 (en) | Pharmaceutical composition for treatment of male sexual dysfunction | |
MD3644F1 (en) | Preparation for algodismenorrhea treatment | |
PL1817029T3 (pl) | Pochodna izoksazolowa do łagodzenia bólu neuropatycznego | |
MY154883A (en) | A combination composition | |
UA97950C2 (ru) | Применение флибансерина для лечения расстройств полового влечения в постклимактерический период |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |